Securities Registration: Employee Benefit Plan (s-8)
24 Aprile 2023 - 11:23PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on April 24, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
biote Corp.
(Exact name
of registrant as specified in its charter)
|
|
|
Delaware |
|
85-1791125 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S Employer
Identification No.) |
|
|
1875 W. Walnut Hill Ln #100
Irving, Texas |
|
75038 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
biote Corp. 2022 Equity Incentive Plan
biote Corp. 2022 Employee Stock Purchase Plan
(Full Title of the Plan)
Teresa S. Weber
Chief
Executive Officer
biote Corp.
1875 W. Walnut Hill Ln #100
Irving, TX 75038
(Name
and address of agent for service)
Tel: (312) 212-8079
(Telephone number, including area code, of agent for service)
Copies to:
Ryan
Sansom
Peter Byrne
Cooley LLP
500 Boylston
Street
Boston, MA 02116-3736
Tel: (617) 937-2300
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting
company and emerging growth company in Rule 12b-2 of the Exchange Act:
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Pursuant to General Instruction E of Form S-8, biote Corp. (the Registrant) is filing this
Registration Statement with the Securities and Exchange Commission (the Commission) to register (i) an additional 4,498,916 shares of Class A common stock, par value $0.0001 (the common stock), under the biote Corp.
2022 Equity Incentive Plan (the 2022 Plan) and (ii) an additional 797,724 shares of common stock under the biote Corp. 2022 Employee Stock Purchase Plan (the 2022 ESPP and together with the 2022 Plan, the
Plans), in each case pursuant to the provisions of each Plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under such Plan. In accordance with the instructional note to Part I
of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement. Pursuant to General
Instruction E to Form S-8, the contents of Registrants registration statement on Form S-8 (File No. 333-266490), previously filed with the Commission on August 3, 2022, are incorporated herein by reference, except that the provisions contained
in Part II of such earlier Registration Statement are modified as set forth in this Registration Statement.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:
|
(a) |
the Registrants annual report on Form
10-K for the fiscal year ended December 31, 2022 filed with the Commission on March 29, 2023; |
|
(c) |
the description of the Registrants securities contained in the registration statement on Form
8-A (File No. 333-265714) filed with the Commission on February 26, 2021 and any amendment or report filed with the Commission for the purpose of updating
the description. |
All reports and other documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), other than current reports furnished under Item 2.02 and Item 7.01 of Form 8-K and any exhibits furnished on such form
that relate to such items, after the date of this registration statement, and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining
unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated
herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.
1
Item 8. Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
4.1 |
|
Second Amended and Restated Certificate of Incorporation of biote Corp. (Incorporated by reference to Exhibit 3.1 to the Companys Current
Report on Form 8-K (File No. 001-40128) filed by the Company with the Commission on June 2, 2022). |
|
|
4.2 |
|
Amended and Restated Bylaws of biote Corp. (Incorporated by reference to Exhibit 3.1 to the Companys Current Report on Form 8-K (File No. 001-40128), filed by the Company with the Commission on February 22, 2023). |
|
|
5.1 |
|
Opinion of Cooley LLP. |
|
|
23.1 |
|
Consent of Deloitte & Touche LLP. |
|
|
23.2 |
|
Consent of Cooley LLP (included in Exhibit 5.1). |
|
|
24.1 |
|
Power of Attorney (contained on the signature page hereto). |
|
|
99.1 |
|
biote Corp. 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.17 to the Companys Annual Report on Form
10-K, filed by the Company with the Commission on March 29, 2023). |
|
|
99.2 |
|
biote Corp. 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 of the Companys Registration Statement on Form
S-8, filed by the Company with the Commission on August 3, 2022). |
|
|
99.3 |
|
Form of Stock Option Grant Notice (incorporated by reference to Exhibit 99.3 of the Companys Registration Statement on Form S-8, filed by the Company with the Commission on August 3, 2022). |
|
|
99.4 |
|
Form of RSU Award Grant Notice (incorporated by reference to Exhibit 99.4 of the Companys Registration Statement on Form S-8, filed by the Company with the Commission on August 3, 2022). |
|
|
107 |
|
Filing Fee Table |
2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8, and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irving,
Texas on April 24, 2023.
|
|
|
biote Corp. |
|
|
By: |
|
/s/ Teresa S. Weber |
Name: |
|
Teresa S. Weber |
Title: |
|
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Teresa S. Weber and Samar
Kamdar, as his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution for him or her and in his or her name, place and
stead, in any and all capacities to sign any and all amendments including post-effective amendments to this registration statement and any and all registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as
amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, hereby ratifying and confirming all that
said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following
persons in the capacities and on the dates indicated.
|
|
|
|
|
Name |
|
Position |
|
Date |
|
|
|
/s/ Teresa S. Weber
Teresa S. Weber |
|
Chief Executive Officer, Director |
|
April 24, 2023 |
|
|
|
/s/ Samar Kamdar
Samar Kamdar |
|
Chief Financial Officer |
|
April 24, 2023 |
|
|
|
/s/ Marc D. Beer
Marc D. Beer |
|
Director, Chair |
|
April 24, 2023 |
|
|
|
/s/ Dana Jacoby
Dana Jacoby |
|
Director |
|
April 24, 2023 |
|
|
|
/s/ Mark Cone
Mark Cone |
|
Director |
|
April 24, 2023 |
|
|
|
/s/ Steven J. Heyer
Steven J. Heyer |
|
Director |
|
April 24, 2023 |
|
|
|
/s/ Andrew R. Heyer
Andrew R. Heyer |
|
Director |
|
April 24, 2023 |
|
|
|
/s/ Debra L. Morris
Debra L. Morris |
|
Director |
|
April 24, 2023 |
3
Grafico Azioni Haymaker Acquisition Cor... (NASDAQ:HYAC)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Haymaker Acquisition Cor... (NASDAQ:HYAC)
Storico
Da Feb 2024 a Feb 2025
Notizie in Tempo Reale relative a Haymaker Acquisition Corporation III (NASDAQ): 0 articoli recenti
Più Biote Corp. Articoli Notizie